Abstract: A compound represented by following formula I: according to the present disclosure. The disclosed compound is useful in the treatment of many disease states related to cell proliferation. In particular, new pyran derivatives are provided along with processes for preparations and methods for pharmaceutical applications, for example, as anticancer agents. The compound was found to have antiproliferative effects against multiple cancer cell lines and showed low toxicity to normal fibroblasts. The disclosed compound also exhibited anticancer properties by inducing caspase-mediated cell death mechanisms and arresting cancer cell progression. Further, the compound represented by Formula I targets multiple key proteins/enzymes, including thioredoxin reductase, glutathione reductase, transferrin receptors, inisitol-3-phosphate synthase, cystolic aminopeptidase, and transketolase, which are over-expressed in tumor cells.

Abstract: The present invention relates to the prevention, prophylactic and therapeutic treatment of autoimmune diseases including but not limited to multiple sclerosis by administering novel small molecules to a subject in need thereof.

Abstract: The present invention relates to the prevention, prophylactic and therapeutic treatment of autoimmune diseases including but not limited to multiple sclerosis by administering novel small molecules to a subject in need thereof.

Abstract: Novel heterocyclic systems are herein disclosed, which possess many biological activities, including but not limited to anticancer activity. The disclosed compounds are useful in the treatment of many disease states related to cell proliferation. In particular, new pyran derivatives are provided along with processes for their preparations and methods for their pharmaceutical applications, for example, as anticancer agents. These compounds were found to have antiproliferative effects against multiple cancer cell lines and showed low toxicity to normal fibroblasts. The disclosed compounds also exhibited anticancer properties by inducing caspase-mediated cell death mechanisms and arresting cancer cell progression. Further, these novel compounds were able to target multiple key proteins/enzymes, including thioredoxin reductase, glutathione reductase, transferrin receptors, inisitol-3-phosphate synthase, cystolic aminopeptidase, and transketolase, which are over-expressed in tumor cells.

Abstract: Novel heterocyclic fused systems are disclosed herein which possess numerous biological activities, including but not limited to antibacterial activity, and usefulness to the treatment of many disease states, such as pathogenic infections. In particular, new imidazoles are disclosed along with related processes of preparation and methods of use as antibacterial agents. The disclosed compounds were found to be active against several Gram-positive bacteria, including Enterococcus faecalis and Bacillus subtilis, and were also found to be active against several species of multi-drug resistant Staphylococcus, such as S. aureus, S. saprophyticus, S. haemolyticus, and S. epidermidis.

Abstract: Novel heterocyclic systems are herein disclosed, which possess many biological activities, including but not limited to anticancer activity. The disclosed compounds are useful in the treatment of many disease states related to cell proliferation. In particular, new pyran derivatives are provided along with processes for their preparations and methods for their pharmaceutical applications, for example, as anticancer agents. These compounds were found to have antiproliferative effects against multiple cancer cell lines and showed low toxicity to normal fibroblasts. The disclosed compounds also exhibited anticancer properties by inducing caspase-mediated cell death mechanisms and arresting cancer cell progression. Further, these novel compounds were able to target multiple key proteins/enzymes, including thioredoxin reductase, glutathione reductase, transferrin receptors, inisitol-3-phosphate synthase, cystolic aminopeptidase, and transketolase, which are over-expressed in tumor cells.

Abstract: Novel heterocyclic fused systems are disclosed herein which possess numerous biological activities, including but not limited to antibacterial activity, and usefulness to the treatment of many disease states, such as pathogenic infections. In particular, new imidazoles are disclosed along with related processes of preparation and methods of use as antibacterial agents. The disclosed compounds were found to be active against several Gram-positive bacteria, including Enterococcus faecalis and Bacillus subtilis, and were also found to be active against several species of multi-drug resistant Staphylococcus, such as S. aureus, S. saprophyticus, S. haemolyticus, and S. epidermidis.

Abstract: The present invention provides a compound of general formula A for use as a potential anticancer agent against human cancer cell lines and a process for the preparation thereof wherein R is selected from the group consisting of H, F, Cl, Br, OMe, Me and CF3, R1 is selected from the group consisting of H, 4-F, 4-Cl, 4-Br, 4-CF3, 4-OMe, 3,4-OMe, 3,5-OMe and 3,4,5-OMe, and n is an integer ranging from 1-3.

Abstract: The present invention provides a compound of general formula A for use as a potential anticancer agent against human cancer cell lines and a process for the preparation thereof. wherein R is selected from the group consisting of H, F, Cl, Br, OMe, Me and CF3, R1 is selected from the group consisting of H, 4-F, 4-Cl, 4-Br, 4-CF3, 4-OMe, 3,4-OMe, 3,5-OMe and 3,4,5-OMe, and n is an integer ranging from 1-3.